VEGF、脂肪因子与结直肠癌发病相关机制的研究进展

doi:10.12677/WJCR.2022.123022

期刊菜单

VEGF、脂肪因子与结直肠癌发病相关机制的研究进展
Research Progress of VEGF, Adipokine and the Pathogenesis of Colorectal Cancer

DOI: 10.12677/WJCR.2022.123022, PDF,
作者: 成文：昆明理工大学医学院，云南昆明
关键词: 结直肠癌、血管内皮细胞生长因子、脂肪因子；Colorectal Cancer； Vascular Endothelial Cell Growth Factor； Adipokine

摘要: 结直肠癌作为一种新发病例及死亡病例均在全世界排名前列的癌症，其发病机制尚需深入研究。血管内皮细胞生长因子能促进新生血管的生成，在肿瘤增殖、侵袭和迁移过程中起到重要作用。脂肪因子包括瘦素、脂联素、网膜素、细胞因子等，这些脂肪因子与结直肠癌的发生发展密切相关。本文就结直肠癌发生发展进程与血管内皮细胞生长因子及脂肪因子之间的关系及血管内皮细胞生长与脂肪因子之间的联系进行综述，期望为防治结直肠癌提供积极的理论依据。

Abstract: Colorectal cancer is a cancer with a high incidence of new cases and deaths in the world, and its pathogenesis needs to be further studied. Vascular endothelial cell growth factor can promote the formation of new blood vessels and play an important role in the process of tumor proliferation, invasion and migration. Adipokines include leptin, adiponectin, retinin and cytokines, and these adipokines are closely related to the occurrence and development of colorectal cancer. This paper reviews the relationship between the occurrence and development of colorectal cancer and vascular endothelial cell growth factor and adipokine as well as the relationship between vascular endothelial cell growth factor and adipokine, hoping to provide a positive theoretical basis for the prevention and treatment of colorectal cancer.

文章引用：成文. VEGF、脂肪因子与结直肠癌发病相关机制的研究进展[J]. 世界肿瘤研究, 2022, 12(3): 161-166. https://doi.org/10.12677/WJCR.2022.123022

参考文献

[1]	Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2]	Bergers, G. and Hanahan, D. (2008) Modes of Resistance to Anti-Angiogenic Therapy. Nature Reviews Cancer, 8, 592-603. [Google Scholar] [CrossRef] [PubMed]
[3]	Ellis, L.M. and Reardon, D.A. (2010) Is There Really a Yin and Yang to VEGF-Targeted Therapies? The Lancet Oncology, 11, 809-811. [Google Scholar] [CrossRef]
[4]	Meadows, K.L. and Hurwitz, H.I. (2012) Anti-VEGF Therapies in the Clinic. Cold Spring Harbor Perspectives in Medicine, 2, a006577. [Google Scholar] [CrossRef] [PubMed]
[5]	Jayson, G.C., Kerbel, R., Ellis, L.M. and Harris, A.L. (2016) Antiangiogenic Therapy in Oncology: Current Status and Future Directions. The Lancet, 388, 518-529. [Google Scholar] [CrossRef]
[6]	Mohamed, S.Y., Mohammed, H.L., Ibrahim, H.M., Mohamed, E.M. and Salah, M. (2019) Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Case. Journal of Gastrointestinal Cancer, 50, 23-34. [Google Scholar] [CrossRef] [PubMed]
[7]	Bhattacharya, R., Ye, X.C., Wang, R., Ling, X., McManus, M., Fan, F., Boulbes, D. and Ellis, L.M. (2016) Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Research, 76, 3014-3024. [Google Scholar] [CrossRef]
[8]	Gerber, H.P., Dixit, V. and Ferrara, N. (1998) Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells. Journal of Biological Chemistry, 273, 13313-13316. [Google Scholar] [CrossRef] [PubMed]
[9]	Tomida, C., Nagano, H., Yamagishi, N., et al. (2017) Regorafenib Induces Adaptive Resistance of Colorectal Cancer Cells via Inhibition of Vascular Endothelial Growth Factor Receptor. The Journal of Medical Investigation, 64, 262-265. [Google Scholar] [CrossRef] [PubMed]
[10]	Appiah-Kubi, K., Wang, Y., Qian, H., Wu, M., Yao, X., Wu, Y. and Chen, Y. (2016) Platelet-Derived Growth Factor Receptor/Platelet-Derived Growth Factor (PDGFR/PDGF) System Is a Prognostic and Treatment Response Biomarker with Multifarious Therapeutic Targets in Cancers. Tumor Biology, 37, 10053-10066. [Google Scholar] [CrossRef] [PubMed]
[11]	Katoh, M. and Nakagama, H. (2014) FGF Receptors: Cancer Biology and Therapeutics. Medicinal Research Reviews, 34, 280-300. [Google Scholar] [CrossRef] [PubMed]
[12]	Simon, T., Gagliano, T. and Giamas, G. (2017) Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Trends in Molecular Medicine, 23, 282-292. [Google Scholar] [CrossRef] [PubMed]
[13]	Friedman, J. (2014) 20 Years of Leptin: Leptin at 20: An Overview. Journal of Endocrinology, 223, T1-T8. [Google Scholar] [CrossRef]
[14]	Candelaria, P.V., Rampoldi, A., Harbuzariu, A., et al. (2017) Leptin Signaling and Cancer Chemoresistance: Perspectives. World Journal of Clinical Oncology, 8, 106-119. [Google Scholar] [CrossRef] [PubMed]
[15]	Sharma, D., Saxena, N.K., Vertino, P.M. and Anania, F.A. (2006) Leptin Promotes the Proliferative Response and Invasiveness in Human Endometrial Cancer Cells by Activating Multiple Signal-Transduction Pathways. Endocrine-Related Cancer, 13, 629-640. [Google Scholar] [CrossRef] [PubMed]
[16]	Choi, J.H., Park, S.H., Leung, P.C.K. and Choi, K.C. (2005) Expression of Leptin Receptors and Potential Effects of Leptin on the Cell Growth and Activation of Mitogen-Activated Protein Kinases in Ovarian Cancer Cells. The Journal of Clinical Endocrinology & Metabolism, 90, 207-210. [Google Scholar] [CrossRef] [PubMed]
[17]	Mantzoros, C.S., Magkos, F., Brinkoetter, M., Sienkiewicz, E., Dardeno, T.A., Kim, S.Y., et al. (2011) Leptin in Human Physiology and Pathophysiology. American Journal of Physiology-Endocrinology and Metabolism, 301, E567-E584. [Google Scholar] [CrossRef] [PubMed]
[18]	Booth, A., Magnuson, A., Fouts, J. and Foster, M. (2015) Adipose Tissue, Obesity and Adipokines: Role in Cancer Promotion. Hormone Molecular Biology and Clinical Investigation, 21, 57-74. [Google Scholar] [CrossRef] [PubMed]
[19]	Dauer, D.J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R. and Haura, E.B. (2005) Stat3 Regulates Genes Common to Both Wound Healing and Cancer. Oncogene, 24, 3397-3408. [Google Scholar] [CrossRef] [PubMed]
[20]	Komiya, M., Fujii, G., Takahashi, M., Shimura, M., Noma, N., Shimizu, S., Onuma, W. and Mutoh, M. (2014) Bi-Directional Regulation between Adiponectin and Plasminogen Activator-Inhibitor-1 in 3T3-L1 Cells. In Vivo, 28, 13-19. http://iv.iiarjournals.org/content/28/1/13.full
[21]	Otani, K., Ishihara, S., Yamaguchi, H., et al. (2017) Adiponectin and Colorectal Cancer. Surgery Today, 47, 151-158. [Google Scholar] [CrossRef] [PubMed]
[22]	Spyrou, N., Avgerinos, K.I., Mantzoros, C.S. and Dalamaga, M. (2018) Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies. Current Obesity Reports, 7, 260-275. [Google Scholar] [CrossRef] [PubMed]
[23]	Moon, H.S., Liu, X., Nagel, J.M., et al. (2013) Salutary Effects of Adiponectin on Colon Cancer: In Vivo and in Vitro Studies in Mice. Gut, 62, 561-570. [Google Scholar] [CrossRef] [PubMed]
[24]	Nigro, E., Schettino, P., Polito, R., et al. (2018) Adiponectin and Colon Cancer: Evidence for Inhibitory Effects on Viability and Migration of Human Colorectal Cell Lines. Molecular and Cellular Biochemistry, 448, 125-135. [Google Scholar] [CrossRef] [PubMed]
[25]	张群慧. 网膜素-1对结直肠癌干细胞增殖凋亡的影响及机制研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2017.
[26]	Harvey, A.E., Lashinger, L.M. and Hursting, S.D. (2011) The Growing Challenge of Obesity and Cancer: An Inflammatory Issue. Annals of the New York Academy of Sciences, 1229, 45-52. [Google Scholar] [CrossRef] [PubMed]
[27]	Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L. and Karin, M. (2009) IL-6 and Stat3 are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer. Cancer Cell, 15, 103-113. [Google Scholar] [CrossRef] [PubMed]
[28]	Beg, A.A. and Baltimore, D. (1996) An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death. Science, 274, 782-784. [Google Scholar] [CrossRef] [PubMed]
[29]	Suman, S., Kallakury, B.V.S., Fornace Jr., A.J. and Datta, K. (2015) Protracted Upregulation of Leptin and IGF1 Is Associated with Activation of PI3K/Akt and JAK2 Pathway in Mouse Intestine after Ionizing Radiation Exposure. International Journal of Biological Sciences, 11, 274-283. [Google Scholar] [CrossRef] [PubMed]
[30]	Fazolini, N.P.B., Cruz, A.L.S., Werneck, M.B.F., Viola, J.P.B., Maya-Monteiro, C.M. and Bozza, P.T. (2015) Leptin Activation of mTOR Pathway in Intestinal Epithelial Cell Triggers Lipid Droplet Formation, Cytokine Production and Increased Cell Proliferation. Cell Cycle, 14, 2667-2676. [Google Scholar] [CrossRef] [PubMed]
[31]	Song, M.Y., Gong, J., Giovannucci, E.L., Berndt, S.I., Brenner, H., et al. (2015) Genetic Variants of Adiponectin and Risk of Colorectal Cancer. International Journal of Cancer, 137, 154-164. [Google Scholar] [CrossRef] [PubMed]
[32]	Aleksandrova, K., di Giuseppe, R., Isermann, B., Biemann, R., Schulze, M., Wittenbecher, C., Fritsche, A., Lehmann, R., Menzel, J., Weikert, C., Pischon, T. and Boeing, H. (2016) Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data from the EPIC-Potsdam Cohort Study. Cancer Research, 76, 3862-3871. [Google Scholar] [CrossRef]
[33]	Vivanco, I. and Sawyers, C.L. (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nature Reviews Cancer, 2, 489-501. [Google Scholar] [CrossRef] [PubMed]
[34]	Fazeli, M.S., Dashti, H., Akbarzadeh, S., Assadi, M., Aminian, A., Keramati, M.R. and Nabipour, I. (2013) Circulating Levels of Novel Adipocytokines in Patients with Colorectal Cancer. Cytokine, 62, 81-85. [Google Scholar] [CrossRef] [PubMed]

为你推荐

友情链接